Atezolizumab Plus Bevacizumab Does Not Improve OS in Renal Cell Carcinoma
The overall survival results were similar between the treatment arms for the overall cohort and for patients with PD-L1+ disease.
Kidney Cancer
Oral Targeted Agents for Metastatic RCC Associated With Higher Risk of Adverse Events
A retrospective study sought to determine the risk of adverse events with the use of TKIs and mTOR inhibitors for renal cell carcinoma in patients with renal impairment or ESRD.
New Agent for VHL-Associated Kidney Cancer Lauded
Belzutifan makes von Hippel-Lindau disease more manageable, according to an expert.
COVID-19 Vaccines Deemed Safe for Renal Cell Carcinoma Patients on Immune Checkpoint Inhibitors
The rate of new or worsening immune-related adverse events was no higher than previously reported.
Cytoreductive Nephrectomy Plus Active Surveillance Benefits Some With Metastatic Renal Cell Carcinoma
The median cancer-specific survival was 56.5 months.
Managing Adverse Reactions to Lenvatinib-Pembrolizumab
The median time to first onset of key adverse reactions was within 5 months of starting lenvatinib-pembrolizumab.
Gene Expression Profiling Could Inform Treatment of Non-Clear Cell Renal Cell Carcinoma
Nearly half of non-clear cell renal cell carcinoma samples were classified as proliferative.
Predicting Long-Term Survival With Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma
Patients with smaller target lesions at baseline were more likely to be long-term survivors.
High IC and HU Associated With Better Outcomes in Metastatic Renal Cell Carcinoma
Iodine concentration and Hounsfield units were associated with treatment response and survival.
ICIs Linked With Higher Risk for Cancer Therapy-Related Cardiac Dysfunction
In a study presented at AHA 2021, researchers aimed to assess the link between cancer therapy-related cardiac dysfunction and immune checkpoint inhibitors.
- Loading...
Loading...
Next post in Kidney Cancer
Loading... 
Loading...